 | • レポートコード：MRC2303K036 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：バイオ |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界のリキッドバイオプシー市場規模が、予測期間中（2022年-2027年）、CAGR 16.7％で増大すると予測されています。本レポートでは、リキッドバイオプシーの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患別（肺がん、乳がん、大腸がん、その他）分析、種類別（循環腫瘍細胞、循環腫瘍DNA、セルフリーDNA）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Bio-Rad Laboratories、Diagnologix LLC、Exosome Sciences Inc.、Grail Inc.、Guardant Health、Horizon Discovery、Inivata Ltd、Illumina Inc.、LungLife AI Inc.、Qiagen NVなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のリキッドバイオプシー市場規模：疾患別 - 肺がんにおける市場規模 - 乳がんにおける市場規模 - 大腸がんにおける市場規模 - その他疾患における市場規模 ・世界のリキッドバイオプシー市場規模：種類別 - 循環腫瘍細胞の市場規模 - 循環腫瘍DNAの市場規模 - セルフリーDNAの市場規模 ・世界のリキッドバイオプシー市場規模：地域別 - 北米のリキッドバイオプシー市場規模 アメリカのリキッドバイオプシー市場規模 カナダのリキッドバイオプシー市場規模 メキシコのリキッドバイオプシー市場規模 … - ヨーロッパのリキッドバイオプシー市場規模 ドイツのリキッドバイオプシー市場規模 イギリスのリキッドバイオプシー市場規模 フランスのリキッドバイオプシー市場規模 … - アジア太平洋のリキッドバイオプシー市場規模 中国のリキッドバイオプシー市場規模 日本のリキッドバイオプシー市場規模 インドのリキッドバイオプシー市場規模 … - 南米/中東のリキッドバイオプシー市場規模 南アフリカのリキッドバイオプシー市場規模 ブラジルのリキッドバイオプシー市場規模 アルゼンチンのリキッドバイオプシー市場規模 … ・競争状況 ・市場機会・将来動向 |
The fluid biopsy market is estimated to register a CAGR of 16.7% over the forecast period, 2022-2027.
Globally, the COVID-19 outbreak impacted all aspects of the healthcare sector, including the fluid biopsy market, as there are major disruptions to businesses and economic activities worldwide. The number of patient visits to hospitals, ambulance surgery centers, clinics, and diagnostic centers dropped dramatically, though emergency and outpatient services were available in cardiology, neurology, and other departments. The COVID-19 pandemic impacted the global healthcare systems and resulted in disruptive general healthcare, placing high-risk cancer patients at great risk. For example, a study titled ‘Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study’, published in 2020, reported that 356 centers from 54 countries across the six continents participated between April 21 and May 8, 2020. These institutions register 716,979 new cancer patients a year. The majority of them (88.2%) reported that they were facing challenges in delivering care during the outbreak. Although 55.34% reduced their resources as part of a strategic plan, other common reasons include the full program (19.94%), lack of defense equipment (19.10%), staff shortages (17.98%), and limited access to medicines (9.83%). Diagnostic testing is still the backbone of the response to COVID-19, supporting the content efforts of various organizations. In addition, the complexity of the problem and the growing power problems associated with polymerase-chain-reaction (PCR-based) testing accelerated the development of diagnostic solutions to meet the need for multidisciplinary testing. Therefore, COVID-19 impacted the diagnostic testing market and the fluid biopsy market.
In 2020, the World Health Organization reported that cancer was the leading cause of death worldwide, with an estimated 10 million deaths. The most common (according to new cancer cases) were breast cancer (2.26 million cases); lungs (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million patients); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases). By 2030, the global burden is expected to grow to 21.7 million new cancers and 13 million cancer deaths, which may be due to the aging population.
The cancer burden is expected to be even greater due to the adoption of western lifestyles and choices, such as smoking, malnutrition, physical inactivity, and fewer births, in economically developed countries. The need for early detection of cancer may contribute to the growth of the global market. Liquid biopsy was much needed for the diagnosis of solid tissues and others.
Different types of cancer, such as non-small cell lung cancer, head and neck cancer, breast cancer, lymphomas, leukemia, and breast and liver cancer, can be diagnosed early with the help of liquid biopsy. These are the five most common types of cancer that affect people worldwide, along with bowel, stomach, and liver cancers. Thus, the increasing incidence of cancer is boosting the fluid biopsy market.
Fluid Biopsy Market Trends
Breast Cancer is Expected to Record High CAGR During the Forecast Period
Breast cancer is the most common cancer among women and the fifth leading cause of mortality. Incidence rates vary greatly worldwide. The prevalence of breast cancer is increasing, particularly in developing countries, where a majority of the cases are diagnosed at later stages. According to the World Health Organization, in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. As of 2020, there were 7.8 million women diagnosed with breast cancer in the past five years, making it the world’s most prevalent cancer.
Early detection and treatment reduce the mortality rate. A biopsy is the only diagnostic procedure that can determine if the suspicious area is cancerous. A breast biopsy test removes tissue or sometimes fluid from the suspicious area, and the removed cells are examined under a microscope and further tested to check for the presence of breast cancer.
Liquid biopsies are a reliable alternative to conventional biopsies, offering a potentially cheaper, easier, and less invasive way of monitoring malignancies.
Patients can be tested more frequently. This method provides accurate results, as genetic sequencing of free-floating tumor DNA captures the diversity of genetic alterations found in cancer cells, in different body parts, including the primary tumor and metastases.
These tests are gaining traction within the diagnostic industry. The fluid biopsy market is expected to grow due to the increasing incidences of breast cancer.
The various liquid biopsy platforms (circulating tumor cells (CTCs) and cell-free DNA (cfDNA) and exosomes) added tremendous value to the care of breast cancer patients. Lung cancer and breast cancer hold the major share of the fluid biopsy market.
North America Dominates the Market, and May Continue a Similar Trend During the Forecast Period
North America is expected to dominate the overall market during the forecast period. The United States holds the largest market share because cancer is the second most common cause of death in the country, thus boosting the growth of the fluid biopsy market. According to the American Cancer Society Inc., in 2021, there were an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States. In addition, according to the Johns Hopkins School of Medicine, the elderly population is at high risk of getting affected by cancer. According to the World Ageing Report 2019, the senior population is expected to increase from 53.340 million in 2019 to 83.813 million in 2050. Thus, the growing geriatric population is expected to result in a high cancer incidence, thus contributing to the market’s growth.
Moreover, the Memorial Sloan Kettering Cancer Center received a major grant from the US National Institutes of Health (NIH) to conduct research related to leukemia, largely focusing on AML. Such investments in the concerned market may drive the growth of the market. Thus, the market is expected to grow significantly over the forecast period due to the above-mentioned factors.
Fluid Biopsy Market Competitor Analysis
The fluid biopsy market is competitive and consists of a few major players. In terms of market share, these players currently dominate the market. Some of the major players are Bio-Rad Laboratories, LungLife AI Inc. (Cynvenio), Guardant Health, Horizon Discovery, and Qiagen.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand for Non-invasive Procedures
4.2.2 Increasing Number of Cancer Cases Worldwide
4.3 Market Restraints
4.3.1 Growth of Alternative Technologies like Optical Biopsies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Indication
5.1.1 Lung Cancer
5.1.2 Breast Cancer
5.1.3 Colorectal
5.1.4 Other Indications
5.2 By Type
5.2.1 Circulating Tumor Cells
5.2.2 Circulating Tumor DNA
5.2.3 Cell-free DNA
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bio-Rad Laboratories
6.1.2 Diagnologix LLC
6.1.3 Exosome Sciences Inc.
6.1.4 Grail Inc.
6.1.5 Guardant Health
6.1.6 Horizon Discovery
6.1.7 Inivata Ltd
6.1.8 Illumina Inc.
6.1.9 LungLife AI Inc.
6.1.10 Qiagen NV
7 MARKET OPPORTUNITIES AND FUTURE TRENDS